Thank you, afternoon. McDavid good and
make CIMERLI, X. retina We in launch four pipeline progress our are by to next into the market over months, launched product of commercialization new led on the and XX the which October excellent continuing products plan to
begin with UDENYCA. me Let
franchise a market launches share. in UDENYCA on-body retains price and is value growth and strategy share XX% Neulasta of maintain the with that Our XXXX. Onpro share base maximize device to enable trade-offs and to long-term to optimize will between our
So next franchise. of the for share the will as wave the serve market on-body growth segment UDENYCA
Neulasta important quarterly is expected, highest our launch reflected because the pricing is This UDENYCA’s of a in Onpro class. a currently can holds overall with second device ASP ASP we FDA While ASP, be fluctuations our be on-body approval. upon when ASP discipline higher will against evidence advantage which in competitive the
from XX.X%, in impacted Overall quarter, payer competitor and majority of demand units reduced quarter. irreversible Market driven prior which discounting declined quarter. XX%, $XX price in selling coverage by by were the were sales net in and the decline a XX% and in million in decline For the compared third a quarter sequential the clinic decline third The commercial share net was primarily to price. the a markets. UDENYCA biosimilars decline $XX some X% segments respectively, X.X% in by demand non-XXXB the million prior was
our portfolio, biosimilar. CIMERLI, our the YUSIMRY, HUMIRA like our and Now, I’d toripalimab, our includes PD-X to inhibitor, of product rest talk about biosimilar, Lucentis which
as well underway now indicated, commenced now on with revenue the Denny is CIMERLI is Biosimilar pleased the which we very a driver enter $X we are billion growth As and formation anti-VEGF October market launch, commercial X. market.
CIMERLI can and currently interchangeability retinal exclusivity. and patients As outcomes. was the XX confidence specialists indications, that This FDA you received biosimilar fully to strengths all and well giving been as LUCENTIS with complete to FDA-approved X all only they same treated Lucentis transition label and of expect know, has by the the months safely CIMERLI dosage clinical interchangeable them first approved
let X weeks While share some encouraging me with data launch, are you we points. very only the into early
we X,XXX launched July. over to-date, units. biosimilar, Launch first in than sales. sold which is And was our share Biogen month, market in the greater First our
relationships. with no UDENYCA, experienced and reallocating have we decision getting X,XXX in dedicated CIMERLI achieve hire resources reinforces prescribers more have we And this extensive teams This Second, to total teams and by specialists. as existing excellent delivered incremental in retinal are experience account able to our an access who key from than customer retina sales were sales presentations to targeted to headcount. our increase
pathway XXX% for confirmed of Medicare wet coverage submitted and under claims B, is is Medicare on reimbursement fee-for-service Third lives, AMD which of Lucentis market the access. the has of Part enabling XX% patients with CIMERLI majority business. now
a code to for application permanent and we been the launch submitted Q-code has expect in XXXX. QX Our
success least far, project by providers this million. revenues Given and that XXXX of CIMERLI the at so be will reception of the positive launch $XXX we
updated XXXX. will of course keep We launch progresses as time-to-time into from you
excited establish only bring nasopharyngeal new all patients, in therapy, would standard about carcinoma line. we lines and of inhibitor first potential regarding a first be including PD-X oncologists to to Now and the what care and of very toripalimab, are indicated the to for
the scale track be oncology commercial integrated on the field have and toripalimab existing oncology Therefore, built Our Commercial significant toripalimab been to customers preparations have are overlap between trained. targeted teams into prescribers. will capabilities and facing of launch infrastructure. with our been efficiently commercial launch fully UDENYCA
ready will toripalimab upon launch directly to We be FDA approval.
forward billion our and competing large for in look launch Humira’s July regarding Humira preparing this to $XX market. XXXX in YUSIMRY we sales and were December was last by XXXX. are net U.S. Now, we FDA YUSIMRY, biosimilar. in approved
We large million continue formulary in scale With presentation prepared to to price, state-of-the-art have to well decisions is product supply, supply criteria key believe of each YUSIMRY to on will more positioned to are than $XX compete invested and commit and in the serve criteria. and that as these guarantees we used manufacturing. making supply respect
current the or X time year the in have of units manufacturing we YUSIMRY exceeds facility. overall have potential of the the XXX,XXX about million ready At that capacity will to launch, Our for triple we and XX% work units first capacity distribution.
We price. will a enabling a deliver competitive to manufacturer the high-volume, cost us low be ability also highly
Our strategy proposition alignment adalimumab of decision-makers, and well as a with seek possible. the and formulary quickly will payers are biosimilar deliver marketplace. competitive as be thus this We PBMs see significant advantage. is the In as large market we confident as in as make aligned short, we a to possible, value competitor YUSIMRY source the a both as we compelling
an now development will to over call the of Dr. Theresa? our update I pipeline. on for Lavallee the turn
